Detalhe da pesquisa
1.
Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals.
Clin Infect Dis
; 68(3): 446-452, 2019 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-30084943
2.
Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers.
J Antimicrob Chemother
; 74(1): 149-156, 2019 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30272231
3.
Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide.
J Antimicrob Chemother
; 74(6): 1670-1678, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30815689
4.
Targeting Unconventional T Cells for Vaccination against Tuberculosis.
Am J Respir Cell Mol Biol
; 62(4): 401-402, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31801037
5.
Successful direct-acting antiviral therapy in HIV/HCV co-infected patients fails to restore circulating mucosal-associated invariant T cells.
Eur J Immunol
; 49(7): 1127-1129, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30985000
6.
Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers.
J Antimicrob Chemother
; 74(5): 1466, 2019 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30778557
7.
Corrigendum: Comparison of the frequency and phenotypic profile of Mycobacterium tuberculosis-specific CD4 T cells between the site of disease and blood in pericardial tuberculosis.
Front Immunol
; 14: 1141704, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36825021
8.
Blood and Site of Disease Inflammatory Profiles Differ in Patients With Pericardial Tuberculosis and Human Immunodeficiency Virus Type 1.
Open Forum Infect Dis
; 10(3): ofad128, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36998631
9.
Effects of tuberculosis and/or HIV-1 infection on COVID-19 presentation and immune response in Africa.
Nat Commun
; 14(1): 188, 2023 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36635274
10.
Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2.
Nat Med
; 27(8): 1362-1366, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34040262
11.
Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.
Nat Cancer
; 2(12): 1321-1337, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35121900
12.
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study.
Nat Cancer
; 2(12): 1305-1320, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35121899
13.
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study.
Nat Cancer
; 2: 1321-1337, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34950880
14.
Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.
Res Sq
; 2021 Sep 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34580668
15.
Safety implications of combined antiretroviral and anti-tuberculosis drugs.
Expert Opin Drug Saf
; 19(1): 23-41, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31809218
16.
Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin.
Int J Antimicrob Agents
; 54(2): 202-206, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31002950
17.
Global access of rifabutin for the treatment of tuberculosis - why should we prioritize this?
J Int AIDS Soc
; 22(7): e25333, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31318176
18.
Association Between Impaired Vα7.2+CD161++CD8+ (MAIT) and Vα7.2+CD161-CD8+ T-Cell Populations and Gut Dysbiosis in Chronically HIV- and/or HCV-Infected Patients.
Front Microbiol
; 10: 1972, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31555223
19.
Pharmacological impact of antiretroviral therapy on platelet function to investigate human immunodeficiency virus-associated cardiovascular risk.
Br J Pharmacol
; 176(7): 879-889, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30681136
20.
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.
PLoS One
; 12(5): e0177352, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28545127